Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

Anónimo. Rilpivirine et HIV chez les adolescents. Prescrire 2017;37:13-4. [Ref.ID 101362]

Almendrala A. The success of HIV treatment is increasing the risk of drug-resistance. And the threat is growing.. The Huffington Post 2016:1. [Ref.ID 100995]

Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn G, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O'Dell SJ, Jacoki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun T-W. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med 2016:9 de noviembre. [Ref.ID 100922]

Anónimo. UK appeals court rules NHS has authority to fund PrEP medication for HIV. DIA Daily 2016:1. [Ref.ID 100918]

Anónimo. Various states approve recreational, medical marijuana use. DIA Daily 2016:7. [Ref.ID 100907]

Anónimo. Impact of two cases of HIV among PrEP-using patients overblown, HIV experts say. DIA Daily 2016:4. [Ref.ID 100885]

Anónimo. Patients worldwide turning to “buyers clubs” for access to hepatitis C, HIV medications. DIA Daily 2016:7. [Ref.ID 100881]

Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]

Anónimo. UK court rules that NHS can fund HIV PrEP drug. DIA Daily 2016:1. [Ref.ID 100564]

González R, Sevene E, Jagoe G, Slutsker L, Menéndez C. A public health paradox: the women most vulnerable to malaria are the least protected. PLOS Medicine 2016:3 de mayo. [Ref.ID 100350]

Anónimo. India adds 28 new drugs to essential medicines list. DIA Daily 2015:28 de diciembre. [Ref.ID 99744]

Anónimo. Darunavir + cobicistat. Prescrire 2015;35:649. [Ref.ID 99709]

Anónimo. Cobicistat. Prescrire 2015;35:648-9. [Ref.ID 99708]

Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S, GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015;385:2606-15. [Ref.ID 99315]

Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 2015;313:2474-83. [Ref.ID 99309]

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S D, Schmidikofer S, Westwood M, Kleijnen J. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015;313:2456-73. [Ref.ID 99308]

The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373:795-807. [Ref.ID 99275]

Anónimo. Éfavirenz: suicides. Prescrire 2015;35:105. [Ref.ID 98917]